30 March - 31 March 2022
38th SCI Process Development Symposium
Organised by:
Online Webinar
Registration Closed
This event is no longer available for registration.
Share this event
Synopsis
Process Development is the application of chemistry to the scale up of new synthetic processes from the laboratory, through pilot plant to full scale commercial manufacture and into life cycle management. It is an extremely broad discipline, crossing the boundaries between synthetic organic chemistry, process technology and chemical engineering.
The area of Process Development continues to be a challenging and important area for the research into and application of modern synthetic organic chemistry, as well as enabling technologies.
Attendees
The symposium aims to bring together a wide range of speakers from across the Pharmaceutical, Agrochemical and Fine Chemical industries, as well as from an academic background. This meeting brings together experts from across the entire spectrum of the discipline to present state of the art process development.
Exhibition and Sponsorship
For further information and prices please email jacqui.maguire@soci.org
Programme
Day 1 - Wednesday 30 March
- 09.00
- Welcome and introduction to day 1
- 09:05
- Kinetic simulations of complex catalytic reactions
Dr Tom Corrie, Syngenta, UK - 09:50
- Process development and large-scale manufacture of a key intermediate towards AZD9833
Tom Bishop, AstraZeneca, UK - 10:30
- Break
- 10:50
- Late stage NCE process development
Dr Ulrich Scholz, Boehringer Ingelheim, Germany - 11:35
- Discovery and sensitivity in photocatalysis
Prof Dr Frank Glorius, University of Münster, Germany - 12:15
- Lunch
- 13:15
- Organometallics in Flow at GSK: lab to plant
Chris McKay, GlaxoSmithKline, UK - 14:00
- Accelerating chemical process development through data science
Dr Jason M Stevens, Bristol Myers Squibb, USA - 14:40
- Break
- 15:00
- Racing to the finish: the benefit of 3D printed flow reactors in scale-up
Dr Lana Borukhova, InnoSyn B.V., The Netherlands - 15:45
- Process chemistry award winner 2021: Having fun with process research and development
John Blacker, University of Leeds - 16:25
- Closing remarks
- 16:30
- Close of day 1
Day 2 - Thursday 31 March
- 09:00
- Welcome and introduction to day 2
- 09:05
- Angle control and synergistic promotion strategies in asymmetric catalysis
Prof Wanbin Zhang, Jiao Tong University, China - 09:50
- The identification of Naloxone related drug product degradants
Dr John Carey, Indivior, UK - 10:30
- Break
- 10:50
- Process chemistry and catalysis at Roche - capabilities and selected case studies
Dr Stefan Hildbrand, F. Hoffmann-La Roche Ltd - 11:35
- A long journey into MCL-1 inhibitors
Dr Matthieu Jouffroy, Janssen Pharmaceutica N.V., Belgium - 12:15
- Lunch
- 13:15
- Nitrosamine risk assessment in pharmaceuticals
Dr Mike Urqhart GlaxoSmithKline, UK - 14:00
- Leveraging HTE Platforms for Process Chemistry Development at AbbVie
Dr Brian Kotecki, Abbvie, USA - 14:40
- Break
- 15:00
- Process Chemistry Development for the EZH2 Inhibitor PF-06821497
Dr Nick Desrosiers, Pfizer, USA - 15:45
- Process development toward Nemtabrutinib: converting a biorenewable solvent into an API
Dr Ben Turnbull, MSD, USA - 16:25
- Closing remarks
- 16:30
- Close of day 2
Fees
| Before early bird - ends 16 February 2022 SCI Member - £150 Non-member - £200 Student member - £75 |
| After early bird SCI Member - £250 Non-member - £310 Student member - £75 |
All registrations will automatically receive a confirmation within 24 hours of registering for the event. Should you not receive written confirmation of your booking, please email conferences@soci.org.
Become an SCI Member and save on this and future events
See Membership OptionsSign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations
Booking Process/Deadlines
CPD Information
SCI Members attending this meeting are able to claim CPD points.
Sponsors
.ashx?h=1434&w=3052&hash=08F43052D66A4EDA9117ACCA7BB9C93F){kind=logo}
Organising Committee
-
Max Espensen, Pharmaron
-
Louis Diorazio, SCI/AstraZeneca
-
Dave Lathbury, SCI/Astute Chemical Development Ltd
-
David Pascoe, SCI/GlaxoSmithKline
-
Hazmi Tajuddin, SCI/Syngenta
-
Robert Walton, SCI/Pfizer
-
Hilmar Weinman, Janssen Pharmaceutical Companies of Johnson & Johnson
